麦角溴烟酯的治疗用途。

文章的细节

引用

复制到剪贴板

B,宣传Fioravanti M, Dolezal T, Logina我,脚触搞笑,Popescu,所罗门

麦角溴烟酯的治疗用途。

中国药物Investig。2008; 28 (9): 533 - 52。

PubMed ID

18666801 (在PubMed

]

文摘

麦角生物碱导数麦角溴烟酯成为临床上可用大约35年前在1970年代。麦角溴烟酯具有广谱的行动:(i)作为α(1)肾上腺素受体拮抗剂,它诱导血管舒张和动脉血流增加;(2)它能增强胆碱能和含有儿茶酚胺的神经递质功能;(3)抑制血小板聚集;(iv)它促进新陈代谢活动,从而导致增加氧气和葡萄糖的利用率;和(v)神经营养和抗氧化特性。作用于一些基本的病理生理机制,麦角溴烟酯治疗潜在的障碍。本文概述发表的临床证据的有效性和安全性麦角溴烟酯(30毫克每日两次)对痴呆的治疗(包括阿尔茨海默病和血管性痴呆)和血管和平衡失调。老年痴呆症的不同的目的,建立了麦角溴烟酯治疗的好处,高达89%的患者显示改善认知和行为。只有2个月的治疗后,症状改善明显与安慰剂相比,和大多数病人仍改善或稳定后12个月。 Concomitant neurophysiological changes in the brain indicate (after only 4-8 weeks' treatment) improved vigilance and information processing. In patients with balance disorders, mean improvements of 44-78% in symptom severity and quality of life have been observed with nicergoline. Although clinical experience with nicergoline in vascular disorders is limited to relatively short-term, small-scale studies, it has been successfully used in rehabilitation therapy of patients with chronic ischaemic stroke. Open-label evaluations suggest that nicergoline may also be valuable in glaucoma, depression and peripheral arterio-pathy. Adverse events of nicergoline, if any, are related to the central nervous system, the metabolic system and the overall body. Most are considered typical symptoms of ergot derivatives. Because of their generally mild and transient nature, treatment discontinuations occur relatively infrequently. The efficacy of nicergoline combined with a favourable safety and tolerability profile at commonly applied doses (60 mg/day) make this agent a valuable therapy in patients with mild to moderate dementia, vascular diseases and balance disorders.

DrugBank数据引用了这篇文章

药物

麦角溴烟酯